bioRxiv Science⌕ Search
Home/Archive/bioRxiv

bioRxiv · 10.64898/2025.12.11.693520

p53 and YAP/TAZ-TEAD activities determine metaplastic heterogeneity in pancreatic cancer

Martin, C. P.·Bang, S.·Gomes, J. R.·Sullivan, W. B.·Liu, Y. P.·Smith, M. D.·Edwards, A. C.·Der, C. J.·Morris, J. P.
View original source ↗Export metadata ↓

Abstract

BACKGROUND and AIMSPancreatic ductal adenocarcinoma (PDAC) initiation and progression is characterized by lineage plasticity across a continuum of metaplastic and malignant cell fates. This molecular heterogeneity influences disease progression and therapeutic response, yet the genetic and molecular interactions underlying cellular plasticity during PDAC progression remain poorly understood. Here we studied how p53, the most frequently inactivated tumor suppressor in PDAC, interacts with the YAP/TAZ-TEAD transcriptional effector arm of the Hippo pathway to determine cell fate and neoplastic heterogeneity in PDAC development. METHODSWe characterized differentiation states in mouse PDAC and pre-malignant cells in response to p53 activation or inactivation, respectively, and upon genetic, pharmacological, and physiological modulation of YAP/TAZ-TEAD activity. Differentiation was analyzed in vivo in an orthotopic PDAC model permitting independent, inducible control of p53 and TEAD function. We analyzed the effect of p53 and YAP/TAZ-TEAD activity on cell fate in mouse and human PDAC and analyzed markers of clinically relevant molecular subtypes in human PDAC cell lines treated with small molecule TEAD inhibitors. RESULTSRe-engaging wildtype p53 function in KrasMut pancreatic cancer cells increases TEAD activity through accumulation of its co-activator TAZ. Remarkably, increased YAP/TAZ-TEAD activity broadly suppresses the expression of overlapping markers of gastric pit-like (GPL) differentiation and the classical PDAC subtype that are promoted by p53. Accordingly, p53 and YAP/TAZ-TEAD activity inversely correlate with GPL and classical differentiation during PDAC development and modulation of both pathways determines expression of GPL and classical markers in vitro and in vivo. GPL differentiation is acutely sensitive to YAP/TAZ-TEAD activity including oncogenic perturbations of the Hippo pathway, actin dynamics, cell-to-cell contact, and adaptative YAP/TAZ accumulation in response to Ras/MAPK pathway inhibition. Functional repression of gastric-classical differentiation by TEAD persists in human PDAC where potent TEAD inhibition increases expression of GPL and classical markers. CONCLUSIONSWe find that p53 and YAP/TAZ-TEAD activities determine gastric plasticity during PDAC development highlighting the role that key cancer drivers and therapeutically targetable signaling pathways play in active maintenance of cellular identity during pancreatic cancer development.

Explore related subjects

cancer biologyPreprint

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Martin, C. P., Bang, S., Gomes, J. R., Sullivan, W. B., Liu, Y. P., Smith, M. D., Edwards, A. C., Der, C. J., Morris, J. P.. 2025-12-15. p53 and YAP/TAZ-TEAD activities determine metaplastic heterogeneity in pancreatic cancer. https://doi.org/10.64898/2025.12.11.693520

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

m6A-Driven Intratumoral Cholesterol Biosynthesis Fuels Castration-Resistant Prostate Cancer Progression

Both nuclear pore complexes (NPCs) and RNA N6-methyladenosine (m6A) machinery are indispensable for proper cellular function. Although their collaborative roles in the nuclear export of messenger RNAs (mRNAs) have been reported, it remains ambiguous whether and how this collaboration may contribute to cancer progression. Here we identify a functional cooperation between NPCs and m6A signaling that promotes the development of castration-resistant prostate cancer (CRPC). We showed that nuclear export of m6A-modified mRNAs, mediated by the interaction between RNA methyltransferase METTL3 and the nucleoporin NUP93, is functionally coupled to cholesterol biosynthesis. Given that cholesterol-fueled intratumoral androgen production is one of the mechanisms driving CRPC, we demonstrated that overexpression of the wild-type METTL3 or NUP93, but neither the enzymatically dead METTL3 nor the mutant NUP93 that loses METTL3-interacting capability, elevates intracellular levels of androgens, activates AR signaling under castrate condition, and promotes androgen-independent growth of prostate cancer cells both in vitro and in vivo. Importantly, pharmacological inhibition of METTL3 or targeted demethylation on mRNAs encoding key cholesterol biosynthesis enzymes effectively suppressed CRPC malignancy. Together, these findings uncover a therapeutically targetable m6A-METTL3-NUP93 axis that links nuclear mRNA export and metabolic reprogramming to fuel CRPC progression, providing a conceptually new strategy for the treatment of this lethal disease.

cancer biology↗
bioRxiv2026

ST6Gal2 promotes α2,6-sialylation and aggressive phenotypes in neuroblastoma cells

Neuroblastoma is the most common extracranial solid tumor of childhood. Its clinical behavior ranges from spontaneous regression to lethal, treatment-refractory disease. Aberrant 2,6-sialylation contributes to aggressive phenotypes in many cancers, but the role of ST6Gal2, a neural-enriched 2,6-sialyltransferase, in neuroblastoma is largely unexplored. Here, we examine the clinical and functional significance of ST6Gal2 in neuroblastoma. In two independent public cohorts (SEQC, n=498; Kocak, n=649), high ST6GAL2 expression was associated with significantly worse overall and event-free survival. In the SEQC cohort, ST6GAL2 expression was higher in high-risk and MYCN-amplified tumors, varied across International Neuroblastoma Staging System stages, and correlated positively with a mesenchymal transcriptional signature (Spearman {rho}=0.181). The mesenchymal correlation was reproduced in the Kocak cohort ({rho}=0.204). Stable shRNA-mediated knockdown of ST6GAL2 in SK-N-AS and SK-N-BE(2) cells reduced proliferation and viability, impaired wound closure, and decreased migration and invasion. In preliminary experiments in SK-N-AS cells, ST6GAL2 knockdown reduced binding of Sambucus nigra agglutinin, consistent with a role for ST6Gal2 in 2,6-sialylation. Together, these findings link ST6Gal2 expression to aggressive clinical and transcriptional features and pro-tumorigenic phenotypes in neuroblastoma and nominate ST6Gal2-mediated sialylation as a candidate pathway for mechanistic study.

cancer biology↗
bioRxiv2026

Unsupervised transcriptomic analysis of paired pre- and post-treatment specimens reveals divergent chemoimmunomodulatory induction trajectories in breast cancer

The immunomodulatory effects of chemotherapy (chemoimmunomodulation; CIM) are clinically consequential and heterogeneous, yet no systematic framework exists for classifying the immunomodulatory trajectory a tumor follows in response to treatment (CIM trajectory). Here, we present the CIM Induction Classifier (CIMIC), an unsupervised clustering pipeline leveraging delta gene expression across 3,189 CIM-related genes to classify specimens chemoimmunomodulatory trajectory. Applied to two pre- and post-chemotherapy breast cancer (BC) datasets (NKI/SMC, N = 36; NEO, N = 19) and nine epirubicin-perturbed triple-negative BC (TNBC) cell lines, CIMIC identified two divergent CIM trajectories: a functional CIM (Fun-CIM) trajectory, broadly conserved across tumors and cell lines and characterized by induction of inflammatory cell death, antigen presentation, viral mimicry, and adaptive immune activation programs, and a dysfunctional CIM (Dys-CIM) trajectory, characterized by induction of proteostatic and metabolic stress-adaptation programs, reduced immune cell abundances and cytotoxic activity, and enrichment of aggressive BC subtypes. Using survival and longitudinal transcriptomic data in NKI/SMC (N = 20), treatment-induced increases in Fun-CIM-associated genes and ssGSEA scores were associated with reduced recurrence, whereas Dys-CIM-associated genes and scores were associated with increased recurrence. In multivariable analyses within independent chemotherapy-treated BC cohorts (METABRIC, N = 412; SCAN-B, N = 2,462), higher baseline Fun-CIM ssGSEA scores were associated with better outcomes, whereas higher baseline Dys-CIM ssGSEA scores were associated with worse outcomes. These findings establish CIM as a dynamic, trajectory-level process and position CIMIC as a framework for defining CIM trajectories and supporting future efforts to identify predictors, mechanisms, and therapeutic strategies that maximize beneficial CIM.

cancer biology↗